Related Experiment Videos

Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study

P James1, H H Tan, R MacAlpine

  • 1University Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, UK. PeterJ@memo.dundee.ac.uk

Diabetic Medicine : a Journal of the British Diabetic Association
|September 24, 2004
PubMed

Insights

Lipid-lowering therapy significantly reduces cardiovascular disease risks. However, a notable gap exists in Tayside, Scotland, between diabetic patients needing this therapy and those receiving it, indicating a need for improved secondary prevention strategies.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacotherapy

Background:

  • Lowering cholesterol is a proven strategy for reducing morbidity and mortality in high-risk individuals with existing cardiovascular disease.
  • Secondary prevention of cardiovascular events is critical for patient outcomes.

Purpose of the Study:

  • To assess the utilization of lipid-lowering therapy for secondary prevention among all diabetic patients in Tayside, Scotland.
  • To identify disparities in lipid-lowering drug prescription for patients with diabetes and macrovascular disease.

Main Methods:

  • Utilized the DARTS database to identify diabetic patients (Type 1 and Type 2) with prevalent macrovascular disease in Tayside.
  • Accessed MEMO's pharmacy prescription database to determine lipid-lowering drug uptake.
  • Analyzed demographic and clinical factors associated with therapy use.

Main Results:

  • Among Type 1 diabetes patients with macrovascular disease, only 42.2% used lipid-lowering therapy. Smokers and those with prior coronary heart disease history were more likely to receive it.
  • In Type 2 diabetes patients, 26.7% with macrovascular disease received lipid-lowering therapy. Smokers, those with prior coronary heart disease or angina, and a shorter duration since the first macrovascular event were associated with increased use.
  • Older age (over 70) was linked to a reduced likelihood of receiving lipid-lowering therapy.

Conclusions:

  • A significant gap exists between the number of diabetic patients requiring lipid-lowering therapy and those actually receiving it in Tayside.
  • Current lipid-lowering therapy use for secondary prevention in diabetic patients is suboptimal.
  • Further interventions are needed to bridge the gap in secondary cardiovascular disease prevention for diabetic populations.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...